Pfizer Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparable period ended April 2, 2023. Pfizer is a global biopharmaceutical company; Biopharma is its only reportable segment. The quarter includes Seagen, acquired in December 2023. International subsidiaries report on a quarter-end date of February 25, 2024.
Financial performance
- Revenue: $14.879 billion, down 20% year over year (19% operationally). U.S. revenue grew 9% to $9.514 billion, while international revenue fell 45% to $5.365 billion.
- Key product trends: Comirnaty revenue was $354 million, down 88%; Paxlovid was $2.035 billion, down 50%. Excluding both COVID-19 products, revenue increased 11% operationally. Vyndaqel family revenue rose 66% to $1.137 billion; Eliquis rose 9% to $2.040 billion. Seagen products contributed $742 million.
- Profit and EPS: GAAP net income attributable to Pfizer shareholders was $3.115 billion, down from $5.543 billion. Diluted EPS was $0.55 versus $0.97. Non-GAAP adjusted income was $4.674 billion and adjusted diluted EPS was $0.82, versus $7.036 billion and $1.23, respectively.
- Costs and margins: Cost of sales fell 31% to $3.379 billion and was 22.7% of revenue, compared with 26.4%; this implies a gross margin of approximately 77.3%, calculated from the reported cost-of-sales ratio. R&D was $2.493 billion, roughly flat; intangible amortization rose 19% to $1.308 billion.
- Cash flow: Operating cash flow was $1.090 billion, compared with $1.212 billion. Investing activities provided $1.732 billion, including $3.491 billion from the partial Haleon sale. Financing activities used $4.931 billion, including $2.372 billion of dividends and $1.250 billion of long-term debt repayments.
- Liquidity and debt: Cash and cash equivalents were $719 million and short-term investments were $11.209 billion at quarter-end. Current assets were $42.415 billion and current liabilities $40.497 billion. Short-term borrowings were $8.232 billion and long-term debt $61.307 billion. Pfizer reported access to $15 billion in committed U.S. revolving credit facilities; essentially all credit lines were unused at filing.
- Other metrics: Total assets were $221.095 billion and shareholders’ equity was $92.282 billion. The effective tax rate was 8.6%, compared with 11.4%.
Material changes and notable items
- Revenue declined mainly because of lower Comirnaty and Paxlovid sales. Pfizer cited COVID-19 market transitions, seasonality, and lower international demand; growth elsewhere included Seagen products and Vyndaqel and Eliquis.
- Q1 included a $771 million non-cash favorable Paxlovid return adjustment, reflecting fewer U.S. government treatment courses returned than previously estimated. Pfizer also agreed to supply a 1.0 million-course U.S. Strategic National Stockpile without charge to the government.
- Net interest expense increased to $661 million from $141 million, primarily reflecting acquisition-related financing and lower investment balances. Pfizer recorded a $150 million gain on the partial Haleon sale; the sale generated $3.5 billion in proceeds and reduced its ownership to approximately 23%.
- Pfizer acquired Seagen for $44.2 billion in December 2023. The purchase-price allocation remains provisional. Q1 included $102 million of restructuring and certain acquisition-related costs; reported amortization also increased following the acquisition.
- Pfizer’s multi-year cost realignment program is expected to incur approximately $2.8 billion of costs through 2024. Management expects at least $4 billion of net cost savings, primarily by 2023–2024. Seagen integration is expected to produce approximately $1 billion of annual synergies by 2026, with approximately $1.5 billion of related one-time costs through 2025.
Outlook, commentary and risks
- The filing excerpt does not provide a clear full-year 2024 revenue or earnings guidance value. Pfizer expects approximately 90% of 2024 Comirnaty revenue in the second half, mostly in Q4, and expects most Paxlovid revenue in 2024 to come through commercial channels.
- Management’s stated priorities include oncology leadership, pipeline innovation, growth of newer products, cost-base realignment, and capital allocation. Pfizer declared a $0.42-per-share dividend in April, payable June 14, 2024. No share repurchases were made in Q1.
- Risks include patent expiries and generic competition—described as a moderate revenue impact in 2024–2025 and more significant in 2026–2030—pricing and reimbursement pressures, uncertainty in COVID-19 demand, clinical and regulatory outcomes, and Seagen integration and synergy execution.
- Pfizer’s Rocky Mount, North Carolina manufacturing site was damaged by a 2023 tornado. Manufacturing has resumed, but supply effects are expected through 2024; additional losses, costs, or insurance recoveries remain uncertain. The company also cites ongoing legal and government matters, including product liability and patent disputes; it cannot estimate the reasonably possible loss above accrued amounts.
Important facts for investors to verify
- Whether COVID-19 product demand, commercial-market transitions, and the timing of seasonal Comirnaty sales support management’s expectations.
- Progress on Seagen integration, provisional acquisition accounting, and the timing and costs of expected synergies.
- Realization of cost savings relative to restructuring and implementation costs.
- Potential financial effects of patent expiries, pricing policy changes, litigation, and manufacturing disruption.
- Cash generation, debt reduction, and the use of proceeds from the Haleon sale alongside dividend commitments.